Status:

RECRUITING

DFT383 in Pediatric Participants With Nephropathic Cystinosis

Lead Sponsor:

Novartis Pharmaceuticals

Conditions:

Nephropathic Cystinosis

Eligibility:

All Genders

2-5 years

Phase:

PHASE1

PHASE2

Brief Summary

An open-label, multi-center, phase I/II study to assess the safety, tolerability and efficacy of DFT383 in pediatric participants with nephropathic cystinosis, followed by a long-term extension phase....

Detailed Description

This study is an open-label, multi-center, phase I/II study to assess the safety, tolerability, and efficacy of DFT383 in participants aged 2 to 5 years with nephropathic cystinosis, followed by a lon...

Eligibility Criteria

Inclusion

  • Key Inclusion Criteria:
  • Participants eligible for inclusion in this study must meet all the following criteria:
  • Informed consent in writing from parent(s) or legal guardian(s) must be provided
  • 2 to 5 years of age (including 5 years and 364 days old) at Screening
  • Weight-for-stature is ≥ the third percentile, and is ≥ 10 kg
  • Oral cysteamine therapy for at least 6 months
  • Historic clinical diagnosis of nephropathic cystinosis
  • Laboratory evidence of of renal fanconi syndrome (RFS)
  • Relatively preserved kidney function (eGFR ≥ 60mL/min/1.73m2)
  • Received all age-appropriate vaccinations
  • Key exclusion Criteria for Cohort 1 and 0
  • A history of kidney transplantation
  • A prior or planned bone marrow or stem cell transplantation or prior treatment with gene therapy
  • History of malignancy
  • A severe or uncontrolled medical disorder
  • Major surgery within 90 days
  • Additional Key exclusion criteria for Cohort 1 - The following exclusion criterion applies to Cohort 1 only as it is related to DFT383 treatment:
  • 1\. Indomethacin within 2 weeks prior to Screening
  • Other protocol-defined inclusion/exclusion criteria may apply.

Exclusion

    Key Trial Info

    Start Date :

    June 2 2025

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    March 14 2044

    Estimated Enrollment :

    30 Patients enrolled

    Trial Details

    Trial ID

    NCT06910813

    Start Date

    June 2 2025

    End Date

    March 14 2044

    Last Update

    November 7 2025

    Active Locations (4)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (4 locations)

    1

    University of California at San Diego - Rady Children's Hospital

    San Diego, California, United States, 92123

    2

    Stanford University - Stanford Children's Health

    Stanford, California, United States, 94305

    3

    Emory University School of Medicine - Children's Healthcare of Atlanta (recuiting Cohort 0)

    Atlanta, Georgia, United States, 30322

    4

    Baylor College of Medicine - Texas Children's Hospital (recuiting Cohort 0)

    Houston, Texas, United States, 77030